mesalamine has been researched along with Colonic Diseases in 24 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Colonic Diseases: Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery." | 9.19 | Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. ( Barrett, K; Jamal, MM; Kamm, MA; Márquez, J; Melzer, E; Raskin, JB; Schoen, RE; Streck, P; Szalóki, T, 2014) |
| "We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis." | 9.17 | A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013) |
| "We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery." | 5.19 | Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. ( Barrett, K; Jamal, MM; Kamm, MA; Márquez, J; Melzer, E; Raskin, JB; Schoen, RE; Streck, P; Szalóki, T, 2014) |
| "We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis." | 5.17 | A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013) |
| " Mesalazine suppository was given to her for about 4 months, and glutamine capsules for 2 months, but the rectal ulcer remained unhealed." | 4.12 | Platelet-rich plasma for the treatment of chronic rectal ulcer: A case report. ( Ge, D; Li, P; Li, Y; Liu, G; Liu, J; Liu, Z; Wang, H; Wang, L; Zhao, G, 2022) |
| "Endoscopic postoperative recurrences occur early after 'curative' surgery for Crohn's disease." | 2.68 | Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). ( Belaiche, J; Cortot, A; Daurat, M; Dupas, JL; Faucheron, JL; Florent, C; Gendre, JP; Jacquet, N; Lerebours, E; Malafosse, M; Michot, F; Modigliani, R; Quandale, P; Rothman, N; Sahmound, T; Sarfaty, E; Soulé, JC; Valleur, P, 1996) |
| "The aetiology of Crohn's disease still remains obscure, therefore medical therapy is directed towards symptomatic relief in active disease and relapse prevention in the long-term setting." | 2.42 | Review article: medical treatment of mild to moderately active Crohn's disease. ( Löfberg, R, 2003) |
| "We report a case of Crohn's disease in a 32-year old Saudi male." | 1.31 | Crohn's disease presenting as life-threatening ileal bleeding. ( Ahmad, TM; Al-Been, H; De Keersmaecker, J; Tysk, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, G | 1 |
| Li, Y | 2 |
| Wang, L | 1 |
| Li, P | 1 |
| Liu, Z | 1 |
| Liu, J | 2 |
| Ge, D | 1 |
| Zhao, G | 1 |
| Wang, H | 1 |
| Tursi, A | 3 |
| Cassieri, C | 1 |
| Colucci, R | 1 |
| Elisei, W | 1 |
| Picchio, M | 1 |
| Brandimarte, G | 1 |
| Sato, S | 1 |
| Yashiro, M | 1 |
| Matsuoka, N | 1 |
| Kawana, S | 1 |
| Asano, T | 1 |
| Kobayashi, H | 1 |
| Tasaki, K | 1 |
| Watanabe, H | 1 |
| Hashimoto, Y | 1 |
| Migita, K | 1 |
| Leoncini, G | 1 |
| Villanacci, V | 1 |
| Marin, MG | 1 |
| Crisafulli, V | 1 |
| Cadei, M | 1 |
| Antonelli, E | 1 |
| Leoci, C | 1 |
| Bassotti, G | 1 |
| Stollman, N | 1 |
| Magowan, S | 1 |
| Shanahan, F | 1 |
| Quigley, EM | 1 |
| Raskin, JB | 2 |
| Kamm, MA | 2 |
| Jamal, MM | 1 |
| Márquez, J | 1 |
| Melzer, E | 1 |
| Schoen, RE | 1 |
| Szalóki, T | 1 |
| Barrett, K | 1 |
| Streck, P | 2 |
| Danese, S | 1 |
| Floch, MH | 1 |
| Bain, JA | 1 |
| Zhang, L | 1 |
| Wang, C | 1 |
| Yuan, P | 1 |
| Xin, Y | 1 |
| Otley, A | 1 |
| LeLeiko, N | 1 |
| Langton, C | 1 |
| Lerer, T | 1 |
| Mack, D | 1 |
| Evans, J | 1 |
| Pfefferkorn, M | 1 |
| Carvalho, R | 1 |
| Rosh, J | 1 |
| Griffiths, A | 1 |
| Oliva-Hemker, M | 1 |
| Kay, M | 1 |
| Bousvaros, A | 1 |
| Stephens, M | 1 |
| Samson, C | 1 |
| Grossman, A | 1 |
| Keljo, D | 1 |
| Markowitz, J | 1 |
| Hyams, J | 1 |
| Epifano, F | 1 |
| Genovese, S | 1 |
| Carlucci, G | 1 |
| Locatelli, M | 1 |
| Löfberg, R | 1 |
| Kobayashi, T | 1 |
| Shikuwa, S | 1 |
| Matuoka, Y | 1 |
| Ito, M | 1 |
| Isomoto, H | 1 |
| Kohno, S | 1 |
| Florent, C | 1 |
| Cortot, A | 1 |
| Quandale, P | 1 |
| Sahmound, T | 1 |
| Modigliani, R | 1 |
| Sarfaty, E | 1 |
| Valleur, P | 1 |
| Dupas, JL | 1 |
| Daurat, M | 1 |
| Faucheron, JL | 1 |
| Lerebours, E | 1 |
| Michot, F | 1 |
| Belaiche, J | 1 |
| Jacquet, N | 1 |
| Soulé, JC | 1 |
| Rothman, N | 1 |
| Gendre, JP | 1 |
| Malafosse, M | 1 |
| Wahl, C | 1 |
| Liptay, S | 1 |
| Adler, G | 2 |
| Schmid, RM | 1 |
| Glasbrenner, B | 1 |
| Güthner, C | 1 |
| Röcken, C | 1 |
| Mattfeld, T | 1 |
| Hetzel, W | 1 |
| Allgayer, H | 1 |
| Böhne, P | 1 |
| Kruis, W | 1 |
| Tysk, C | 1 |
| De Keersmaecker, J | 1 |
| Al-Been, H | 1 |
| Ahmad, TM | 1 |
| Gaia, E | 1 |
| Sambatoro, A | 1 |
| De Giuli, P | 1 |
| Angeli, A | 1 |
| Ward, VM | 1 |
| Dua, S | 1 |
| Morrison, GA | 1 |
| Bakowski, MT | 1 |
| Prescott, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period[NCT00554099] | Phase 2 | 117 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.[NCT00545740] | Phase 3 | 590 participants (Actual) | Interventional | 2007-11-28 | Completed | ||
| A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.[NCT00545103] | Phase 3 | 592 participants (Actual) | Interventional | 2007-12-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 12
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Placebo | -16.14 |
| Mesalamine | -17.63 |
| Mesalamine & Probiotic | -16.11 |
GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 52
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Placebo | -16.82 |
| Mesalamine | -17.30 |
| Mesalamine & Probiotic | -16.00 |
GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Placebo | 7.3 |
| Mesalamine | 4.4 |
| Mesalamine & Probiotic | 5.9 |
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 41.4 |
| Mesalamine | 62.5 |
| Mesalamine & Probiotic | 48.1 |
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 52 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 50.0 |
| Mesalamine | 66.7 |
| Mesalamine & Probiotic | 29.2 |
At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit). (NCT00554099)
Timeframe: 12 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 20.0 |
| Mesalamine | 12.5 |
| Mesalamine & Probiotic | 11.8 |
At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit). (NCT00554099)
Timeframe: 52 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 31.0 |
| Mesalamine | 28.1 |
| Mesalamine & Probiotic | 37.0 |
(NCT00554099)
Timeframe: 12 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 2.4 |
| Mesalamine | 5.0 |
| Mesalamine & Probiotic | 0.0 |
(NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 2.8 |
| SPD476 (2.4 g) | 2.8 |
| SPD476 (4.8 g) | 3.3 |
| Placebo | 2.0 |
CT-recurrence of diverticulitis is defined as: a positive spiral CT scan for diverticulitis showing, at a minimum, fat stranding with or without bowel wall thickening >5 mm or surgical intervention for diverticular disease. Withdrawals considered as CT-recurrences. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 61.5 |
| SPD476 (2.4 g) | 62.2 |
| SPD476 (4.8 g) | 52.7 |
| Placebo | 63.9 |
Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 62.2 |
| SPD476 (2.4 g) | 62.9 |
| SPD476 (4.8 g) | 52.7 |
| Placebo | 64.6 |
A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | Number of CT scans (Number) | |||
|---|---|---|---|---|
| Negative | Presence of abdominal pain | 15% increase in WBC from baseline | Presence of abdominal pain + 15% increase in WBC | |
| Placebo | 3 | 3 | 1 | 1 |
| SPD476 (1.2 g) | 0 | 0 | 0 | 0 |
| SPD476 (2.4 g) | 3 | 2 | 1 | 0 |
| SPD476 (4.8 g) | 2 | 2 | 0 | 0 |
A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | Number of CT scans (Number) | |||
|---|---|---|---|---|
| Positive | Presence of abdominal pain | 15% increase in WBC from baseline | Presence of abdominal pain + 15% increase in WBC | |
| Placebo | 1 | 1 | 0 | 0 |
| SPD476 (1.2 g) | 0 | 0 | 0 | 0 |
| SPD476 (2.4 g) | 0 | 0 | 0 | 0 |
| SPD476 (4.8 g) | 1 | 1 | 0 | 0 |
A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | Number of CT scans (Number) | |||
|---|---|---|---|---|
| Negative | Presence of abdominal pain | 15% increase in WBC from baseline | Presence in abdominal pain + 15% increase in WBC | |
| Placebo | 10 | 7 | 1 | 1 |
| SPD476 (1.2 g) | 19 | 19 | 5 | 5 |
| SPD476 (2.4 g) | 10 | 8 | 2 | 2 |
| SPD476 (4.8 g) | 5 | 5 | 2 | 2 |
A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks
| Intervention | Number of CT scans (Number) | |||
|---|---|---|---|---|
| Positive | Presence of abdominal pain | 15% increase in WBC from baseline | Presence in abdominal pain + 15% increase in WBC | |
| Placebo | 38 | 37 | 24 | 23 |
| SPD476 (1.2 g) | 37 | 30 | 17 | 17 |
| SPD476 (2.4 g) | 39 | 39 | 24 | 24 |
| SPD476 (4.8 g) | 55 | 54 | 28 | 28 |
(NCT00545103)
Timeframe: up to 104 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 4.7 |
| SPD476 (2.4 g) | 2.7 |
| SPD476 (4.8 g) | 2.0 |
| Placebo | 1.4 |
CT-recurrence of diverticulitis is defined as: a positive spiral CT scan for diverticulitis showing, at a minimum, fat stranding with or without bowel wall thickening >5 mm or surgical intervention for diverticular disease. Withdrawals considered as CT-recurrences. (NCT00545103)
Timeframe: up to 104 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 62.8 |
| SPD476 (2.4 g) | 59.2 |
| SPD476 (4.8 g) | 69.1 |
| Placebo | 66.9 |
Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences. (NCT00545103)
Timeframe: up to 104 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| SPD476 (1.2 g) | 62.8 |
| SPD476 (2.4 g) | 59.2 |
| SPD476 (4.8 g) | 69.1 |
| Placebo | 67.6 |
A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks
| Intervention | Number of CT Scans (Number) | |||
|---|---|---|---|---|
| Negative | Presence of abdominal pain | 15% increase in WBC from baseline | Abdominal pain + 15% increase in WBC | |
| Placebo | 0 | 0 | 0 | 0 |
| SPD476 (1.2 g) | 1 | 1 | 0 | 0 |
| SPD476 (2.4 g) | 0 | 0 | 0 | 0 |
| SPD476 (4.8 g) | 0 | 0 | 0 | 0 |
A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks
| Intervention | Number of CT Scans (Number) | |||
|---|---|---|---|---|
| Positive | Presence of abdominal pain | 15% increase in WBC from baseline | Abdominal pain + 15% increase in WBC | |
| Placebo | 1 | 1 | 0 | 0 |
| SPD476 (1.2 g) | 0 | 0 | 0 | 0 |
| SPD476 (2.4 g) | 0 | 0 | 0 | 0 |
| SPD476 (4.8 g) | 1 | 0 | 0 | 0 |
A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks
| Intervention | Number of CT Scans (Number) | |||
|---|---|---|---|---|
| Negative | Presence of abdominal pain | 15% increase in WBC from Baseline | Abdominal pain + 15% increase in WBC | |
| Placebo | 15 | 12 | 4 | 3 |
| SPD476 (1.2 g) | 9 | 8 | 1 | 1 |
| SPD476 (2.4 g) | 8 | 6 | 2 | 2 |
| SPD476 (4.8 g) | 22 | 17 | 4 | 4 |
A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 Weeks
| Intervention | Number of CT Scans (Number) | |||
|---|---|---|---|---|
| Positive | Presence of abdominal pain | 15% increase in WBC from baseline | Abdominal pain + 15% increase in WBC | |
| Placebo | 30 | 29 | 11 | 11 |
| SPD476 (1.2 g) | 49 | 48 | 23 | 23 |
| SPD476 (2.4 g) | 45 | 39 | 24 | 22 |
| SPD476 (4.8 g) | 35 | 34 | 18 | 18 |
3 reviews available for mesalamine and Colonic Diseases
| Article | Year |
|---|---|
Balsalazide in treating colonic diseases.
Topics: Colitis, Ulcerative; Colonic Diseases; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines | 2009 |
Novel prodrugs for the treatment of colonic diseases based on 5-aminosalicylic acid, 4'-geranyloxyferulic acid, and auraptene: biological activities and analytical assays.
Topics: Animals; Colonic Diseases; Coumaric Acids; Coumarins; Humans; Mesalamine; Prodrugs | 2012 |
Review article: medical treatment of mild to moderately active Crohn's disease.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal; Colonic Diseases; Crohn Diseas | 2003 |
3 trials available for mesalamine and Colonic Diseases
| Article | Year |
|---|---|
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacter | 2013 |
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin | 2014 |
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin | 2014 |
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin | 2014 |
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin | 2014 |
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Anastomosis, Surgical; Anti-Inf | 1996 |
18 other studies available for mesalamine and Colonic Diseases
| Article | Year |
|---|---|
Platelet-rich plasma for the treatment of chronic rectal ulcer: A case report.
Topics: Capsules; Colonic Diseases; Female; Glutamine; Humans; Mesalamine; Platelet-Rich Plasma; Rectal Dise | 2022 |
Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
Topics: Aged; Budesonide; Colonic Diseases; Diverticular Diseases; Drug Administration Schedule; Drug Therap | 2019 |
Behçet disease associated with gastrointestinal amyloidosis manifested as hematochezia: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Colchicine; Colon; Colonic Diseases; Gastr | 2018 |
Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy.
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Colonic Diseases; Drug Therapy, Combina | 2018 |
Preventing diverticulitis recurrence by selecting the right therapy for a complex disease.
Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans; | 2014 |
Preventing diverticulitis: mesalamine may still be indicated in the decision.
Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans; | 2015 |
Reply: To PMID 25167986.
Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans; | 2015 |
Mesalamine-induced fever: an important reminder to prescribers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Fever; Humans; Male; Mesalamine; Middle A | 2015 |
[Study on novel colon position pulsatile capsule and its release in vitro].
Topics: Capsules; Colonic Diseases; Drug Delivery Systems; Humans; Mannans; Mesalamine; Technology, Pharmace | 2010 |
Budesonide use in pediatric Crohn disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Budesonide; Child; Colon; Colo | 2012 |
Cobblestone appearance in the colon of a 24-year-old man.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Combined Modality Therapy; Diarrhe | 2008 |
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidan | 1998 |
[56-year-old patient with segmental florid colitis and colonic amyloidosis].
Topics: Amyloidosis; Azathioprine; Colitis; Colonic Diseases; Colonoscopy; Crohn Disease; Diagnosis, Differe | 1999 |
Drug-induced fibrosing colonopathy in inflammatory bowel disease after 5-ASA?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Fibrosis; Humans; Mesalamine; Proctocolit | 1999 |
Crohn's disease presenting as life-threatening ileal bleeding.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colectomy; Colonic Diseases; Critical Illnes | 2000 |
Adult fibrosing colonopathy associated with mesalazine treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Female; Fibrosis; Humans; Mesalamine; Mid | 2001 |
Oro-facial granulomatosis: a laryngeal presentation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Female; Granuloma, Laryngeal; Huma | 2001 |
Lack of evidence for fibrosing colonopathy by 5-ASA in humans.
Topics: Acrylic Resins; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Drug Hypersensitivity; Hu | 2002 |